Forward Science has announced the launch of PerioStōm, an FDA-cleared non-drug oral wound dressing designed to protect the oral mucosa following iatrogenic procedures such as scaling and root planing (SRP). The product represents a significant advancement in periodontal care, utilizing chitosan microspheres to enhance post-procedural healing and improve treatment outcomes.
"This is one of those once-in-a-lifetime products," stated Forward Science CEO Robert Whitman. "Our team has worked tirelessly to develop this innovative product over the past decade, and we are excited to provide clinicians with a cost-effective solution that meets the highest standards of quality."
Innovative Technology and Formulation
PerioStōm's formulation centers around chitosan microspheres, a biocompatible polymer recognized for its antimicrobial, anti-inflammatory, and anti-biofilm properties. Research has demonstrated chitosan's effectiveness in inhibiting biofilm formation and combating periodontal pathogens, particularly Porphyromonas gingivalis, making it an ideal agent for post-SRP care.
The product features an advanced delivery system with a curved stainless-steel tip that matches the diameter of a standard curette. This design enables clinicians to apply the dressing precisely at the base of periodontal pockets, ensuring optimal coverage and effectiveness.
Dr. Brian Pikkula, Forward Science's Chief Scientific Officer, emphasized the product's potential impact: "PerioStōm will be a game changer in the dental industry. I think you hear it too often about new products, but this time it's true. After our longest R&D timeline from concept to launch, the exceptional clinical results speak for themselves."
Clinical Benefits and Mechanism of Action
The chitosan-based formulation provides sustained release of therapeutic effects, offering extended protection to the oral mucosa. This mechanism helps ensure smoother recovery with reduced discomfort for patients undergoing periodontal procedures.
Ellen Myers, Executive Director of Clinical Affairs and Strategic Markets at Forward Science, highlighted the clinical significance: "PerioStōm represents a pivotal advancement in periodontal care. This product directly addresses a long-standing clinical need by enhancing standard periodontal therapy, supporting clinicians in delivering consistent, superior clinical outcomes."
Company Background
Forward Science, a privately held MedTech company based in Houston, Texas, was founded in 2012 by two biomedical engineers with the mission of innovating technology to improve lives. The company's flagship product, OralID, is an award-winning oral cancer screening device that enables clinicians to visualize abnormalities that might be missed during traditional examinations.
Following OralID's success, Forward Science expanded its oral healthcare portfolio to include additional innovative products: SalivaMAX, BioStōm, TheraStōm, OxiStōm, and now PerioStōm. The company maintains complete vertical integration, handling all aspects of product development in-house—from design and manufacturing to commercialization and support—ensuring high-quality standards and superior service.
Market Availability
PerioStōm is now available for order, providing dental professionals with an advanced tool to elevate their standard of care in periodontal treatment. The product joins Forward Science's growing lineup of solutions aimed at addressing critical needs in oral healthcare.
